NASDAQ:GILD 22 December 2025

TrumpRx’s 800-drug increase intensifies tariff threat facing generic drug manufacturers

Shares of U.S. generic drugmakers declined on Wednesday after President Donald Trump announced a schedule for new tariffs. Generic drugs brought into the U.S. could see tariffs reaching 200% starting in 2029. U.S. cash markets were shut.

23 July 2026

NASDAQ:GILD·NASDAQ:VTRS·NYSE:PFE·NYSE:TEVA·Pharmaceuticals·SWX:SDZ

TrumpRx’s 800-Drug List Masks Modest Pharma Price Exposure

TrumpRx currently includes around 10% of the branded drug portfolios offered by pharmaceutical companies taking part in the program, well below the widely cited figure of more than 800 medicines.

17 July 2026

NASDAQ:GILD·NYSE:LLY·NYSE:PFE·Pharmaceuticals

Arcellx stock sticks near $115 after Gilead bid — what could move ACLX next

Arcellx finished Tuesday at $113.75, flat on the day, and then slipped a nickel to $113.70 after the bell—still parked just shy of Gilead’s $115 per share bid. Since the buyout was announced, the stock has surged roughly 77% from its Feb. 20 close.

25 February 2026

NASDAQ:ACLX·NASDAQ:GILD·Stock Market

Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next

Arcellx edged up 0.1% to $113.86 in late-morning trading Tuesday, still trading a touch below the cash offer from Gilead Sciences.

24 February 2026

NASDAQ:ACLX·NASDAQ:GILD·Stock Market

Arcellx stock jumps 78% on Gilead’s $7.8 billion buyout — deal terms, risks and next catalyst

Arcellx shares were up $49.73, or about 77.6%, at $113.84 in midday New York trade on Monday after Gilead Sciences moved to buy the cancer therapy developer. Gilead slipped 0.6% to $150.42.

23 February 2026

NASDAQ:ACLX·NASDAQ:GILD·Stock Market

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Shares of Arcellx surged roughly 78% to $113.92 Monday morning, following news that Gilead Sciences will acquire the cancer therapy maker—pushing the stock close to the buyout price. The takeover puts Arcellx’s valuation as high as $7.8 billion, factoring in a contingent sales-related bonus.

23 February 2026

NASDAQ:ACLX·NASDAQ:GILD·NASDAQ:LEGN·NYSE:JNJ·Stock Market

Gilead (GILD) stock slips as Yeztugo outlook keeps traders on edge

Gilead Sciences Inc slipped 1.8% to $152.94 on Thursday, pulling back from Wednesday’s $155.80 close. Shares have moved within a range of $150.92 to $156.20 during the session.

12 February 2026

NASDAQ:GILD·Stock Market

Gilead stock at 52-week high after FDA Yescarta label change, with earnings next

Gilead Sciences Inc notched a new 52-week high on Friday. The move came after the U.S. Food and Drug Administration signed off on a label update for Yescarta, the cancer cell therapy from its Kite unit, keeping attention on the stock as the week kicks off. Shares climbed 2.1% to $152.50.

8 February 2026

Earnings Reports·NASDAQ:GILD·Stock Market

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Shares of Gilead Sciences slipped 1.3% to $139.19 in Wednesday afternoon trading, retreating after a recent rally as investors weighed new drug-pricing news and an oncology update from the company.

28 January 2026

NASDAQ:GILD·Stock Market

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Shares of Gilead Sciences climbed 2.3% to close at $140.97 on Tuesday, marking a fresh 52-week high and extending their winning streak to five sessions. Trading volume hit roughly 10.5 million shares, surpassing the stock’s 50-day average, according to MarketWatch data.

28 January 2026

Earnings Reports·NASDAQ:GILD·Pharmaceuticals·Stock Market

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Shares of Gilead Sciences climbed $2.46, or 1.8%, to $140.24 Tuesday afternoon, hitting a fresh 12-month peak at $141.69 earlier in the session.

27 January 2026

Earnings Reports·NASDAQ:GILD·Pharmaceutical Industry·Stock Market

Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead Sciences Inc shares climbed 1.36%, ending Monday at $137.78—a new 52-week peak and marking the stock’s fourth consecutive day of gains. Volume topped the usual levels as Gilead outperformed Johnson & Johnson, Pfizer, and Abbott Laboratories, all while U.S. indexes moved higher.

27 January 2026

Biotechnology·NASDAQ:GILD·Stock Market

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences, Inc. shares climbed roughly 0.9% to $137.21 by midday Monday, following a price target boost from BMO Capital Markets. The upgrade highlighted expanding insurance coverage for Gilead’s new HIV prevention injection. Earlier, the stock fluctuated between $133.75 and $137.51.

26 January 2026

NASDAQ:GILD·Pharmaceuticals

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead Sciences shares climbed 3.65%, closing at $135.93 on Friday. The stock gained momentum after fresh breast cancer data refocused attention on the company’s oncology efforts.

24 January 2026

NASDAQ:GILD·Pharmaceutical Industry

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares edged down 0.2% to $124.68 in afternoon trade, after swinging between $122.49 and $126.22 earlier. Bernstein SocGen Group held firm on its Outperform rating and $135 price target, pointing to Yeztugo as a major driver for Gilead’s 2026 forecast. The firm also flagged that the market may be underestimating the boost from re-dosing planned for later this year.

20 January 2026

NASDAQ:GILD·Pharmaceuticals·Stock Market

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead Sciences shares were last up 0.15% at $124.91 on Monday, as investors weighed an analyst note that argued new Medicaid drug-pricing rules would have a limited financial impact on the company’s HIV franchise. Investing.com

30 December 2025

NASDAQ:GILD·Pharmaceuticals

Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences, Inc. ended the Dec. 23, 2025 session modestly higher and was little changed after the closing bell—a calm tape that masks a busy fundamental backdrop heading into a holiday-shortened Christmas Eve trading day.

24 December 2025

NASDAQ:GILD·Stock Market

Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences, Inc. ended the regular session on Monday, December 22, 2025 essentially flat, and the stock showed only a modest change in post-market trading—yet the news flow behind the scenes was anything but quiet.

23 December 2025

NASDAQ:GILD·Stock Market

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual.

22 December 2025

NASDAQ:GILD·Pharmaceutical News

Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Ahead of the U.S. market open on Monday, December 22, 2025, Gilead Sciences, Inc. is in focus for two reasons that matter to both short-term traders and long-term investors: a new U.S. government drug-pricing agreement that could reshape near-term sentiment across big pharma, and fresh late-stage HIV pipeline success that reinforces Gilead’s core franchise heading into 2026. Gilead+1

22 December 2025

NASDAQ:GILD·Stock Market

NASDAQ:GILD 22 December 2025 - 23 July 2026